For the Treatment of Type 2 Diabetes, the Vast Majority of Surveyed Physicians in China and South Korea Indicate That Ther

Interviewed South Korean Payers Expect Victoza and Bydureon To Be Reimbursed Under National Health Insurance, According to a New Report from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that in both China and South Korea, the vast majority of surveyed physicians indicate a need for GLP-1 analogues other than Amylin/Eli Lilly’s Byetta and by the end of 2013, Byetta will lose patient share to later-launched GLP-1 analogues in both countries.

Decision Resources’ new Emerging Markets Physician & Payer Forum report entitled Physician and Payer Perspectives on the Market for Injectable Antidiabetics in China and South Korea finds that surveyed Chinese endocrinologists who expect to prescribe GLP-1 analogues over the next two years estimate that more than half of their patients will receive Novo Nordisk’s Victoza. This anticipated favored status in China will be driven by Victoza’s improved clinical efficacy and once daily dosing schedule.

Byetta, the first GLP-1 analogue to launch in China, became available before the 2009 National Reimbursement Drug List (NRDL) published, but was too late for inclusion. Byetta has, however, been added to the Provincial Reimbursement Drug Lists of nine provinces in 2010. Reimbursement of Byetta in selected provinces provides essential data to help the Ministry of Human Resources and Social Security assess the feasibility of Byetta’s inclusion on the NRDL.

“Interviewed payers report that the health insurance fund is under increasing pressure, and express concern that reimbursement of costly GLP-1 analogues would pose substantial financial burden,” said Decision Resources Analyst Jing Wu. “However, in light of the NRDL inclusion of pegylated interferons for hepatitis C virus, we expect Byetta and Victoza to achieve inclusion in the 2013 version of the NRDL, albeit with severe restrictions on eligibility for reimbursement.”

The report also finds that interviewed South Korean payers expect Victoza and Amylin/Eli Lilly/Alkermes’s Bydureon to be reimbursed under the National Health Insurance. However, premium pricing and injectable delivery are the biggest hurdles these agents must overcome if South Korean uptake of the GLP-1 analogues is to increase.

About Emerging Markets Physician & Payer Forum

Emerging Markets Physician & Payer Forum is the industry’s only syndicated primary market research product that includes insights from both physicians and payers to get a true sense of how both parties shape key emerging markets. Emerging Markets Physician & Payer Forum offers analysis of China, South Korea, Brazil and Mexico. Emerging Markets Physician & Payer Forum enables drug developers to understand how payer policy actually impacts prescribing practices in the real world. By drawing on insights from physicians and payers, Emerging Markets Physician & Payer Forum pinpoints key market access levers and barriers that highlight what will drive and/or restrict a brand’s performance, so that drug developers can invest in the most appropriate market access solutions.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Fitness & Nutrition  Pharmaceutical  Professional Services  Insurance  Research  Diabetes  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.